glp-1 agonist fda approval The New Weight Management Meds FDA just approved orforglipron (Foundayo),

How CJC-1295/Ipamorelin affects gut health through GH-mediated tissue repair, gut barrier support, and IGF-1's role in intestinal healing

The estimated treatment difference is therefore 20.4 points under the trial product estimand and 17.3 under treatment policy: a gap of roughly 3.1 points on the effect estimate, not 2.3

doi:10.1002/14651858.CD010308.pub2

Clinical Pharmacokinetics, 42(11), 941967

Freezing reconstituted GHK-Cu isn't ideal because ice crystal formation can damage peptide structure

Since leaky gut occurs once this lining and barrier is compromised, this can cause a myriad of autoimmune symptoms and gut disorders such as dysbiosis